Analysts think ALNY stock price could increase by 1%
Sep 06, 2025, 11:26 AM
6.66%
What does ALNY do
Alnylam Pharmaceuticals, based in Cambridge, Massachusetts, specializes in mRNA cell therapies for autoimmune diseases, with its lead candidate Descartes-08 in Phase IIb trials for generalized myasthenia gravis. The company also develops Descartes-15 and Descartes-33, targeting B cell maturation antigen and autoimmune drivers, respectively.
32 analysts think ALNY stock price will increase by 1.15%. The current median analyst target is $457.47 compared to a current stock price of $452.27. The lowest analysts target is $230.78 and the highest analyst target is $598.50.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.